1篇
您的检索式：作者名="TALENT Study Team"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1:interim analysis of the randomized,controlled,phase 3,non-inferiority TALENT study显示文摘Background:Albuvirtide is a once-weekly injectable human immunodeficiency virus(HIV)-1 fusion inhibitor.We present interim data for a phase 3 trial assessing the safety and efficacy of albuvirtide plus lopinavir-ritonavir in HIV-1-infected adults already treated with antiretroviral drugs.Methods:We carried out a 48-week,randomized,controlled,open-label non-inferiority trial at 12 sites in China.Adults on the World Health Organization(WHO)-recommended first-line treatment for>6 months with a plasma viral load>1000 copies/mL were enrolled and randomly assigned(1:1)to receive albuvirtide(once weekly)plus ritonavir-boosted lopinavir(ABT group)or the WHO-recommended second-line treatment(NRTI group).The primary endpoint was the proportion of patients with a plasma viral load below 50 copies/mL at 48 weeks.Non-inferiority was prespecified with a margin of 12%.Results:At the time of analysis,week 24 data were available for 83 and 92 patients,and week 48 data were available for 46 and 50 patients in the albuvirtide and NRTI groups,respectively.At 48 weeks,80.4%of patients in the ABT group and 66.0%of those in the NRTI group had HIV-1 RNA levels below 50 copies/mL,meeting the criteria for non-inferiority.For the per-protocol population,the superiority of albuvirtide over NRTI was demonstrated.The frequency of grade 3 to 4 adverse events was similar in the two groups;the most common adverse events were diarrhea,upper respiratory tract infections,and grade 3 to 4 increases in triglyceride concentration.Renal function was significantly more impaired at 12 weeks in the patients of the NRTI group who received tenofovir disoproxil fumarate than in those of the ABT group.Conclusions:The TALENT study is the first phase 3 trial of an injectable long-acting HIV drug.This interim analysis indicates that once-weekly albuvirtide in combination with ritonavir-boosted lopinavir is well tolerated and non-inferior to the WHO-recommended second-line regimen in patients with first-line treatment failure.Trial registration:ClinicalTrials.gov Identifier:NCT02369965;http://gffzz90ed6ce9d87f4798sfbb9vc6x0kuk606f.ffgz.tsg.suse.edu.cn Clinical Trial Registry No.ChiCTR-TRC-14004276;http://gffzz62a03ee25e6f4a77hfbb9vc6x0kuk606f.ffgz.tsg.suse.edu.cn/enindex.aspx. | Bin Su Cheng Yao Qing-Xia Zhao Wei-Ping Cai Min Wang Hong-Zhou Lu Yuan-Yuan Chen Li Liu Hui Wang Yun He Yu-Huang Zheng Ling-Hua Li Jin-Feng Chen Jian-Hua Yu Biao Zhu Min Zhao Yong-Tao Sun Wen-Hui Lun Wei Xia Li-Jun Sun Li-Li Dai Tai-Yi Jiang Mei-Xia Wang Qing-Shan Zheng Hai-Yan Peng Yao Wang Rong-Jian Lu Jian-Hua Hu Hui Xing Yi-Ming Shao Dong Xie Tong Zhang Fu-Jie Zhang Hao Wu TALENT Study Team | 2020 | Chinese Medical Journal2020，，24： | 10 |
您所在的机构暂未开通此部分的功能，请联系管理员